Targeted Ptpn11 deletion in mice reveals the essential role of SHP2 in osteoblast differentiation and skeletal homeostasis

Abstract

The maturation and function of osteoblasts (OBs) rely heavily on the reversible phosphorylation of signaling proteins. To date, most of the work in OBs has focused on phosphorylation by tyrosyl kinases, but little has been revealed about dephosphorylation by protein tyrosine phosphatases (PTPases). SHP2 (encoded by PTPN11) is a ubiquitously expressed PTPase. PTPN11 mutations are associated with both bone and cartilage manifestations in patients with Noonan syndrome (NS) and metachondromatosis (MC), although the underlying mechanisms remain elusive. Here, we report that SHP2 deletion in bone gamma-carboxyglutamate protein-expressing (Bglap ⁺) bone cells leads to massive osteopenia in both trabecular and cortical bones due to the failure of bone cell maturation and enhanced osteoclast activity, and its deletion in Bglap ⁺ chondrocytes results in the onset of enchondroma and osteochondroma in aged mice with increased tubular bone length. Mechanistically, SHP2 was found to be required for osteoblastic differentiation by promoting RUNX2/OSTERIX signaling and for the suppression of osteoclastogenesis by inhibiting STAT3-mediated RANKL production by osteoblasts and osteocytes. These findings are likely to explain the compromised skeletal system in NS and MC patients and to inform the development of novel therapeutics to combat skeletal disorders.

References

[1] Nishimura R et al. Osterix regulates calcification and degradation of chondrogenic matrices through matrix metalloproteinase 13 (MMP13) expression in association with transcription factor Runx2 during endochondral ossification. J. Biol. Chem., 2012, 287:33179-33190

[2] Nakashima K et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell, 2002, 108:17-29

[3] Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell, 1997, 89:747-754

[4] Huang W, Zhou X, Lefebvre V, de Crombrugghe B. Phosphorylation of SOX9 by cyclic AMP-dependent protein kinase A enhances SOX9’s ability to transactivate a Col2a1 chondrocyte-specific enhancer. Mol. Cell Biol., 2000, 20:4149-4158

[5] Liu JA et al. Phosphorylation of Sox9 is required for neural crest delamination and is regulated downstream of BMP and canonical Wnt signaling. Proc. Natl Acad. Sci. USA., 2013, 110:2882-2887

[6] Vimalraj S, Arumugam B, Miranda PJ, Selvamurugan N. Runx2: structure, function, and phosphorylation in osteoblast differentiation. Int. J. Biol. Macromol., 2015, 78:202-208

[7] Wee HJ, Huang G, Shigesada K, Ito Y. Serine phosphorylation of RUNX2 with novel potential functions as negative regulatory mechanisms. EMBO Rep., 2002, 3:967-974

[8] Ortuno MJ et al. p38 regulates expression of osteoblast-specific genes by phosphorylation of osterix. J. Biol. Chem., 2010, 285:31985-31994

[9] Choi YH et al. Src enhances osteogenic differentiation through phosphorylation of Osterix. Mol. Cell Endocrinol., 2015, 407:85-97

[10] Maupin KA, Droscha CJ, Williams BO. A comprehensive overview of skeletal phenotypes associated with alterations in Wnt/beta-catenin signaling in humans and mice. Bone Res., 2013, 1:27-71

[11] Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev. Cell, 2005, 8:739-750

[12] Burns, K. A. & Vanden Heuvel, J. P. Modulation of PPAR activity via phosphorylation. Biochim. Biophys. Acta 1771, 952–960 (2007).

[13] Brunmeir, R. & Xu, F. Functional regulation of PPARs through post-translational modifications. Int. J. Mol. Sci. 19, 1738 (2018).

[14] Kawane T et al. Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3. Sci. Rep., 2018, 8

[15] Komori T. Regulation of osteoblast differentiation by Runx2. Adv. Exp. Med Biol., 2010, 658:43-49

[16] Narayanan K et al. Dual functional roles of dentin matrix protein 1. Implications in biomineralization and gene transcription by activation of intracellular Ca²⁺ store. J. Biol. Chem., 2003, 278:17500-17508

[17] Poole KE et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J., 2005, 19:1842-1844

[18] Feng JQ et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet., 2006, 38:1310-1315

[19] Winkler DG et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J., 2003, 22:6267-6276

[20] Balemans W et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet., 2001, 10:537-543

[21] Mundlos S et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell, 1997, 89:773-779

[22] Lapunzina P et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am. J. Hum. Genet., 2010, 87:110-114

[23] Long F, Ornitz DM. Development of the endochondral skeleton. Cold Spring Harb. Perspect. Biol., 2013, 5:a008334

[24] Bonewald LF. The amazing osteocyte. J. Bone Min. Res., 2011, 26:229-238

[25] Graves DT, Jiang Y, Valente AJ. Regulated expression of MCP-1 by osteoblastic cells in vitro and in vivo. Histol. Histopathol., 1999, 14:1347-1354

[26] Lacey DL et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov., 2012, 11:401-419

[27] Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys., 2008, 473:139-146

[28] Hayashi M et al. Osteoprotection by semaphorin 3A. Nature, 2012, 485:69-74

[29] Franzoso G et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev., 1997, 11:3482-3496

[30] Takayanagi H et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature, 2002, 416:744-749

[31] Takayanagi H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell, 2002, 3:889-901

[32] Aoki S et al. Function of OPG as a traffic regulator for RANKL is crucial for controlled osteoclastogenesis. J. Bone Min. Res., 2010, 25:1907-1921

[33] Kobayashi Y, Udagawa N, Takahashi N. Action of RANKL and OPG for osteoclastogenesis. Crit. Rev. Eukaryot. Gene Expr., 2009, 19:61-72

[34] Neel, B. G., Chan, G. & Dhanji, S. SH2 domain-containing protein-tyrosine phosphatases. Handbook of Cell Signaling, 771–809 (2009).

[35] Tartaglia M et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet., 2001, 29:465-468

[36] Araki T et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat. Med., 2004, 10:849-857

[37] Legius E et al. PTPN11 mutations in LEOPARD syndrome. J. Med. Genet., 2002, 39:571-574

[38] Yang W, Neel BG. From an orphan disease to a generalized molecular mechanism: PTPN11 loss-of-function mutations in the pathogenesis of metachondromatosis. Rare Dis., 2013, 1

[39] Yang W et al. Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling. Nature, 2013, 499:491-495

[40] Bowen ME et al. Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome. PLoS Genet., 2011, 7

[41] Sobreira NL et al. Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene. PLoS Genet., 2010, 6

[42] Mansukhani A, Bellosta P, Sahni M, Basilico C. Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J. Cell Biol., 2000, 149:1297-1308

[43] Wang L et al. SHP2 regulates intramembranous ossification by modifying the TGFbeta and BMP2 signaling pathway. Bone, 2019, 120:327-335

[44] Zuo C et al. SHP2 regulates skeletal cell fate by modifying SOX9 expression and 1 transcriptional activity. Bone Res., 2018, 6:12

[45] Zhang M et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol. Chem., 2002, 277:44005-12

[46] Park D et al. Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell, 2012, 10:259-272

[47] Madisen L et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci., 2010, 13:133-140

[48] Nakashima K, de Crombrugghe B. Transcriptional mechanisms in osteoblast differentiation and bone formation. Trends Genet., 2003, 19:458-466

[49] Jing D et al. Tissue clearing of both hard and soft tissue organs with the PEGASOS method. Cell Res., 2018, 28:803-818

[50] O’Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J. Biol. Chem., 1999, 274:19301-19308

[51] Prideaux M, Findlay DM, Atkins GJ. Osteocytes: the master cells in bone remodelling. Curr. Opin. Pharm., 2016, 28:24-30

[52] Atkins GJ et al. RANKL expression is related to the differentiation state of human osteoblasts. J. Bone Min. Res., 2003, 18:1088-1098

[53] Udagawa N et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology, 2000, 141:3478-3484

[54] Nakashima T et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med, 2011, 17:1231-1234

[55] Xiong J et al. Matrix-embedded cells control osteoclast formation. Nat. Med., 2011, 17:1235-1241

[56] Zehender A et al. The tyrosine phosphatase SHP2 controls TGFbeta-induced STAT3 signaling to regulate fibroblast activation and fibrosis. Nat. Commun., 2018, 9

[57] Cha Y, Park KS. SHP2 is a downstream target of ZAP70 to regulate JAK1/STAT3 and ERK signaling pathways in mouse embryonic stem cells. FEBS Lett., 2010, 584:4241-4246

[58] Han Y, Kim CY, Cheong H, Lee KY. Osterix represses adipogenesis by negatively regulating PPARgamma transcriptional activity. Sci. Rep., 2016, 6

[59] Enomoto H et al. Runx2 deficiency in chondrocytes causes adipogenic changes in vitro. J. Cell Sci., 2004, 117:417-425

[60] Wang L et al. SHP2 regulates the osteogenic fate of growth plate hypertrophic chondrocytes. Sci. Rep., 2017, 7

[61] Bowen ME, Ayturk UM, Kurek KC, Yang W, Warman ML. SHP2 regulates chondrocyte terminal differentiation, growth plate architecture and skeletal cell fates. PLoS Genet., 2014, 10

[62] Chan, G. & Neel, B. G. Role of PTPN11 (SHP2) in cancer. in Protein Tyrosine Phosphatases in Cancer In Protein Tyrosine Phosphatases in Cancer (eds Neel, B. G. & Tonks, N. K.) 115–143 (Springer, New York, 2016).

[63] Kim, H. K., Feng, G. S., Chen, D., King, P. D. & Kamiya, N. Targeted disruption of Shp2 in chondrocytes leads to metachondromatosis with multiple cartilaginous protrusions. J. Bone Miner. Res. 29, 761–769 (2014).

[64] Zhou X et al. Multiple functions of Osterix are required for bone growth and homeostasis in postnatal mice. Proc. Natl Acad. Sci. USA., 2010, 107:12919-12924

[65] Komori T et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 1997, 89:755-764

[66] Otto F et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell, 1997, 89:765-771

[67] Tosa I et al. Postnatal Runx2 deletion leads to low bone mass and adipocyte accumulation in mice bone tissues. Biochem. Biophys. Res. Commun., 2019, 516:1229-1233

[68] Huang H et al. A Src family kinase-Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation. Genes Dev., 2012, 26:1587-1601

[69] Zhang SQ et al. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol. Cell, 2004, 13:341-355

[70] Adhami MD et al. Loss of Runx2 in committed osteoblasts impairs postnatal skeletogenesis. J. Bone Min. Res., 2015, 30:71-82

[71] Ikebuchi Y et al. Coupling of bone resorption and formation by RANKL reverse signalling. Nature, 2018, 561:195-200

[72] Zhang W et al. Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia. J. Biol. Chem., 2009, 284:22353-22363

[73] Ohtani T et al. Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity, 2000, 12:95-105

[74] Naka T, Kishimoto T. Joint disease caused by defective gp130-mediated STAT signaling. Arthritis Res., 2002, 4:154-156

[75] Atsumi T et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J. Exp. Med., 2002, 196:979-990

[76] Bergerson JRE, Freeman AF. An update on syndromes with a hyper-IgE phenotype. Immunol. Allergy Clin. North Am., 2019, 39:49-61

[77] Frenkel B et al. Activity of the osteocalcin promoter in skeletal sites of transgenic mice and during osteoblast differentiation in bone marrow-derived stromal cell cultures: effects of age and sex. Endocrinology, 1997, 138:2109-2116

[78] Bakker AD, Klein-Nulend J. Osteoblast isolation from murine calvaria and long bones. Methods Mol. Biol., 2012, 816:19-29

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(RO1AR066746)

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)(1P20 GM119943)